Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer (2022)

Peer-Reviewed Study · Lv S; Wu Z; Luo M; Zhang Y; et al. · September 2022

Lv S et al., 2022-09: Prostate cancer study reporting G0/G1 arrest, apoptosis, DNA damage and reduced AR signalling with ivermectin, and reduced 22RV1 xenograft growth in castrated mice, with FOXA1 and Ku70/Ku80 identified as targets by thermal proteome profiling.

Male mice bearing 22RV1 xenografts were castrated when tumors exceeded 300 mm3 and randomized to vehicle or ivermectin administered 10 mg/kg three times per week. Ivermectin significantly reduced 22RV1 tumor volume growth (n = 5, Fig. 2F), lowering Ki67 and PSA levels and increasing the γH2A.X level in tumor tissue.

n/a (HTML full text, Results)

Lv S et al., 2022-09: Prostate cancer study reporting G0/G1 arrest, apoptosis, DNA damage and reduced AR signalling with ivermectin, and reduced 22RV1 xenograft growth in castrated mice, with FOXA1 and Ku70/Ku80 identified as targets by thermal proteome profiling. Study type: prostate cancer cell lines + castrated-mouse 22RV1 xenograft. N: 5 mice per group. Country: China (Nanfang Hospital, Southern Medical University, Guangzhou). Dose: 10 mg/kg three times per week (route not stated in the quoted passage); comparator: vehicle (DMSO:EtOH:Kalliphor/PBS). Declared COI: 'The authors declare no competing interests.' Also filed as IVA-29 (claims C7, C9). Study type: animal.